About Us
Nkarta is a publicly traded (Nasdaq symbol NKTX), South San Francisco headquartered, clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting.
Founded in 2015 at the birthplace of biotechnology, our development pipeline of engineered NK cell therapy candidates includes two co-lead clinical programs, NKX101 and NKX019. Clinical trials for NKX101 NKX019 are in process. Nkarta recently announced a collaboration with CRISPR Therapeutics, a world leader in gene-based medicines, for the development and commercialization of up to three new cell therapy candidates and access to clinically validated CRISPR/Cas9 genome engineering.
Complementing our broad research and development capabilities, Nkarta has also built an extensive cell therapy manufacturing operation. We have a 2,700-square foot clinical manufacturing facility on-site at our primary corporate location in South San Francisco, California. In-house manufacturing of NKX019 commenced in 2021, and NKX101 in-house manufacturing is planned to begin in 2022. We are also currently designing a separate, larger cGMP facility, to supply our anticipated pivotal clinical trial and commercial needs.
Overview
This role adds to the build out and further development of our growing analytical development team with the advancement of the production and analytics capability for Nkarta\xe2\x80\x99s NK products
Responsibilities
MNCJobz.com will not be responsible for any payment made to a third-party. All Terms of Use are applicable.